GILEAD SCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)
GILEAD SCIENCES, INC. (GILD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss · last filed 2014-02-25
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2012-09-30 was -$1.62M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2011-12-31 was $58.75M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for the quarter ending 2011-09-30 was -$22.68M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2012 was $32.63M, a 7.42% increase from fiscal 2011.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) for fiscal 2011 was $30.38M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$1.62M derived: sum of 2 quarters · filed 2014-02-25 | $32.63M 10-K · filed 2014-02-25 | -$32.63M 10-K · filed 2013-02-27 | |
| 2012-09-30 | -$1.62M 10-Q · filed 2012-11-06 | $32.63M 10-Q · filed 2012-11-06 | |||
| 2012-06-30 | $34.25M 10-Q · filed 2012-08-01 | ||||
| 2011-12-31 | $58.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $36.07M derived: sum of 2 quarters · filed 2013-02-27 | $28.22M derived: sum of 3 quarters · filed 2013-02-27 | $30.38M 10-K · filed 2013-02-27 | |
| 2011-09-30 | -$22.68M 10-Q · filed 2012-11-06 | -$30.54M derived: sum of 2 quarters · filed 2012-11-06 | -$28.38M 10-Q · filed 2012-11-06 | ||
| 2011-06-30 | -$7.85M 10-Q · filed 2012-08-01 | -$5.69M 10-Q · filed 2012-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |